Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Pediatric obesity is targeted
Retatrutide has produced weight loss results that far exceed those of semaglutide (Ozempic), reducing weight by up to 24% in 48 weeks, compared to semaglutides 17.4% reduction after 68 weeks
Ania Jastreboff, MD, PhD, has co-authored numerous research studies on dual- and triple-receptor hormone agonists, including retatrutide
Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
For instance, two obese individuals taking the same dose may experience dramatically different weight loss and fat loss
Researchers comparing concentrations may also review related Retatrutide product pages depending on protocol requirements, documentation needs, and batch availability
US$ 22.92
US$ 20.18
US$ 21.25
US$ 24.02
